The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains - PubMed
The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
M Stanglmaier et al. Leukemia. 2003 Feb.
Abstract
Bcr-Abl is found in more than 95% of cases with CML. The mechanism of Bcr-Abl-induced transformation is not fully understood. Bcr-Abl is a constitutively active tyrosine kinase with transforming capacity for hematopoietic cells. We demonstrated recently that the Src kinase Hck interacts directly with Bcr-Abl by a kinase-independent mechanism. Moreover, the inhibition of the Hck kinase seems to block some of the transforming effects of Bcr-Abl. To identify the binding domains mediating this interaction of Hck with Bcr-Abl, we co-expressed different plasmid and baculovirus vectors containing mutants or single domains of Bcr-Abl and/or Hck in COS7 and Sf9 cells. At least four independent binding regions for Hck were identified in Bcr-Abl, one in Bcr, one in the region comprising the SH3 and SH2 domain of Abl, one in the SH1 domain of Abl, and one in the C-terminal domain of Abl. In the Hck kinase, deletion of the SH2 and/or the SH3 region abolished binding to Bcr-Abl. In contrast, deletion of the Hck SH1 domain enhanced binding of Hck to Abl and Bcr-Abl. In conclusion, the results indicate that the interaction of Bcr-Abl with Hck is mediated by a novel, complex mechanism that involves multiple domains of Bcr-Abl and the SH2 and SH3 domains of Hck.
Similar articles
-
Lionberger JM, Wilson MB, Smithgall TE. Lionberger JM, et al. J Biol Chem. 2000 Jun 16;275(24):18581-5. doi: 10.1074/jbc.C000126200. J Biol Chem. 2000. PMID: 10849448
-
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB. Arlinghaus RB. Oncogene. 2002 Dec 9;21(56):8560-7. doi: 10.1038/sj.onc.1206083. Oncogene. 2002. PMID: 12476302 Review.
-
Reading between the lines: SH3 recognition of an intact protein.
Lim WA. Lim WA. Structure. 1996 Jun 15;4(6):657-9. doi: 10.1016/s0969-2126(96)00071-8. Structure. 1996. PMID: 8805558 Review.
Cited by
-
Maekawa T, Ashihara E, Kimura S. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review.
-
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV. Ichim CV. Stem Cells Transl Med. 2014 Apr;3(4):405-15. doi: 10.5966/sctm.2012-0159. Epub 2014 Mar 5. Stem Cells Transl Med. 2014. PMID: 24598782 Free PMC article. Review.
-
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bernt KM, Hunger SP. Bernt KM, et al. Front Oncol. 2014 Mar 25;4:54. doi: 10.3389/fonc.2014.00054. eCollection 2014. Front Oncol. 2014. PMID: 24724051 Free PMC article. Review.
-
Targeting BCR-ABL1-positive leukaemias: a review article.
Leak S, Horne GA, Copland M. Leak S, et al. Camb Prism Precis Med. 2023 Mar 6;1:e21. doi: 10.1017/pcm.2023.9. eCollection 2023. Camb Prism Precis Med. 2023. PMID: 38550948 Free PMC article. Review.
-
BCR-ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL.
Cao WB, Yao JF, Feng SZ, He Y, Jiang EL, Zhang RL, Yang DL, Gong M, Zheng XH, Chen SL, Sun JL, Zhou LK, Han MZ. Cao WB, et al. Cancer Med. 2018 Jun;7(6):2530-2540. doi: 10.1002/cam4.1478. Epub 2018 Apr 17. Cancer Med. 2018. PMID: 29665256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous